A Phase II trial has also revealed that continuous 5-FU infusion combined with thrice-weekly treatment with IFN-α effectively treats HCC, perhaps because the drugs together play a neoadjuvant role (Patt et al, 2003). This evidence concerns the gene IFNA1 and hepatocellular carcinoma.